Navigation Links
Bionovo Announces Arbitration Decision in Lawsuit Filed by Former Officer - All Claims Denied
Date:6/11/2009

'http://www.bionovo.com' target='_new'>http://www.bionovo.com.

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Bionovo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Bionovo Announces Closing of Public Offering of Common Stock
2. Bionovo Describes a New Class of Therapeutic Compounds
3. Bionovo Announces 2007 Financial Results and Highlights
4. Bionovo to Present at the Cambria Capital Investor Meeting
5. John D. Baxter, M.D. Joins Bionovos Board of Directors
6. Bionovo to Present at the Rodman & Renshaw 10th Annual Global Investment Conference
7. Bionovo to Present Recent Findings of BN108, its Anticancer Agent, at the 31st Annual San Antonio Breast Cancer Symposium
8. Willa A. Hsueh, M.D., Joins Bionovos Scientific Advisory Board
9. Bionovo Announces Cost Control Measures Taken
10. Bionovo Announces Presentation at the National Cancer Institute
11. Jan Ake Gustafsson, M.D., Ph.D., Joins Bionovos Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2014)... policymakers consider ways to ease prohibitions on marijuana, the ... over the past century may provide valuable lessons, according ... that legalized marijuana in Colorado and Washington for recreational ... how to best allow the production, sales and the ... related social ills. , A new study published online ...
(Date:4/20/2014)... Researchers may have identified key genes linked to why ... others, according to a study released today that will ... Annual Meeting in Philadelphia, April 26 to May 3, ... it provides an objective way to understand pain and ... study author Tobore Onojjighofia, MD, MPH, with Proove Biosciences ...
(Date:4/18/2014)... The Gerontologist reports that among older Christians, ... in anxiety about death and increases in life satisfaction, ... particular, listening to gospel music is associated with a ... sense of control. , These associations are similar for ... both low- and high-socioeconomic status. , The article, titled ...
(Date:4/18/2014)... Benaroya Research Institute at Virginia Mason (BRI) recently received ... in metastatic breast cancer reduces both the growth of ... scientists have found in models of the disease that ... 80 percent and can keep the tumor from metastasizing ... grant comes from the National Cancer Institute of the ...
(Date:4/18/2014)... by Northwestern Medicine scientists could lead to potential new ... people with scleroderma. , Fibrosis, or scarring, is ... the skin and lungs can lead to serious organ ... for new therapeutic options centers on findings made by ... identified the role that a specific protein plays in ...
Breaking Medicine News(10 mins):Health News:Regulating legal marijuana could be guided by lessons from alcohol and tobacco, study says 2Health News:Low tolerance for pain? The reason may be in your genes 2Health News:Religious music brings benefit to seniors' mental health 2Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New clues on tissue scarring in scleroderma 2
... that only 2 in 5 seek any assistance, ... being,one of today,s most common disorders, it is regularly ... occasional feelings of anxiety -- muscle tension,headache, nausea, fatigue, ... speaking, first dates, or during times of stress such ...
... Diseases (NIAID), part of the National Institutes of ... Clinical Proteomics Centers for Infectious Diseases and Biodefense. ... Texas Medical Branch (UTMB), Galveston, and to the ... centers will analyze human blood and other tissue ...
... launch anticipated in early 2009 -, CORONA, ... WPI ), a leading specialty pharmaceutical,company, announced today ... approved RAPAFLO(TM) (silodosin), the company,s new alpha blocker ... BPH., BPH is the number one reason ...
... Celestial,Group, Inc. (Nasdaq: HAIN ), a leading ... today announced that Irwin Simon, President and,Chief Executive ... the,Company on Wednesday, October 15, 2008 at the ... http://www.newscom.com/cgi-bin/prnh/20050324/NYTH131 ), The investor presentation ...
... Robbins & Myers, Inc.,(NYSE: RBN ) ... a regular,cash dividend payment of $0.0375 per share. ... shareholders of record as of October 20, 2008., ... supplier of engineered equipment and,systems for critical applications ...
... Oct. 8 New physical activity guidelines,released today ... Services (HHS),will give Americans the information they need ... of the USA, the national resource office for ... Activity Guidelines for Americans set achievable,goals for everyone ...
Cached Medicine News:Health News:40 Million Americans Endure Anxiety Everyday 2Health News:NIAID awards contracts to search for protein markers of disease 2Health News:Watson Receives US FDA Approval for RAPAFLO(TM) (silodosin) for the Treatment of Benign Prostatic Hyperplasia (BPH) 2Health News:Watson Receives US FDA Approval for RAPAFLO(TM) (silodosin) for the Treatment of Benign Prostatic Hyperplasia (BPH) 3Health News:Watson Receives US FDA Approval for RAPAFLO(TM) (silodosin) for the Treatment of Benign Prostatic Hyperplasia (BPH) 4Health News:Hain Celestial to Present at Canaccord Adams Healthy Living Naturally Boston Conference on October 15, 2008 2Health News:YMCA of the USA Supports New National Physical Activity Guidelines 2
(Date:1/15/2014)... Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), a ... a non-invasive, wireless continuous glucose monitoring system, today announced ... Interim CEO of Echo Therapeutics, will present at "TEN", ... Mr. Doman will make a corporate presentation ...
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: PharmaPoint: Atopic ... Analysis to 2022 http://www.reportlinker.com/p01957657/PharmaPoint-Atopic-Dermatitis---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... India Drug Forecast and Market Analysis to ...
(Date:1/15/2014)... Jan. 15, 2014  Zafgen, Inc., a leading biopharmaceutical ... severely obese patients, today announced initial results from ... inhibitor of methionine aminopeptidase 2 (MetAP2), in patients ... genetic obesity.  These results showed improvements in body ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... Argos Therapeutics announced today that interleukin ... dendritic cell (DC) immunotherapy and can be used as a ... company,s lead product, AGS-003, in metastatic renal cell carcinoma (mRCC). ... Immunotherapy demonstrate that the potency of mature CD40L RNA electroporated ...
... Rotational molder REMCON Plastics is already seeing process reduction ... organized under the leadership of new hire Benjamin F. ... REMCON,s Lean Manufacturing and Continuous Improvement Initiatives. He will ... active teams to sustain a strong, lean culture within ...
Cached Medicine Technology:Interleukin (IL)-12 Secretion Can Predict Potency of Argos Therapeutics' Arcelis™ Dendritic Cell (DC) Immunotherapy and Can Be Used as Potency Marker in Phase 3 Clinical Trial 2Interleukin (IL)-12 Secretion Can Predict Potency of Argos Therapeutics' Arcelis™ Dendritic Cell (DC) Immunotherapy and Can Be Used as Potency Marker in Phase 3 Clinical Trial 3Six Sigma Black Belt and Lean Sensei Ben Wittich Joins REMCON Plastics 2
Double-ended. Designated most popular model or size....
Designated most popular model or size. 3 mm tip....
Octagonal handle. 3 mm wide....
4 mm x 6 mm dissector end with shaft marked at 10 mm, 20 mm, 30 mm from tip. 6 mm wide curved elevator. Round knurled handle....
Medicine Products: